Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2010, Article ID 351045, 4 pages
Clinical Study

Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis

1Berrenratherstr. 296, 50937 Köln, Germany
2Durenerstr. 332, 50935 Köln, Germany
3Institute of Medical Statistics and Epidemiology, University of Cologne, 50924 Köln, Germany

Received 4 April 2010; Revised 1 September 2010; Accepted 20 October 2010

Academic Editor: Bruno Brochet

Copyright © 2010 Damian Franzen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Immunosuppressive therapy is an established therapeutic option in patients suffering from multiple sclerosis (MS). In an open nonrandomized study we serially assessed cardiac function in 30 consecutive patients with MS before, during, and after mitoxantrone therapy. Mitoxantrone (12 mg/m2) was administered intravenously at 3-month intervals. Before each infusion, cardiac function was assessed by history taking, resting electrocardiogram, and echocardiography. Whereas no patient experienced clinical signs of heart failure, left ventricular pump function decreased continuously during mitoxantrone therapy and did not recover after cessation. The presented data suggest a dose-dependent and long-lasting toxic cardiac effect of low-dose mitoxantrone therapy in MS.